New brain cancer drug combo enters first human tests
Disease control
Recruiting now
This study tests a new drug called MT-125 given together with standard radiation for people newly diagnosed with a fast-growing brain tumor called glioblastoma. The main goals are to find a safe dose and understand side effects. About 36 adults aged 18 and older with a specific t…
Phase: PHASE1, PHASE2 • Sponsor: Myosin Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC